The role of cyclic nucleotide signaling pathways in cancer: Targets for prevention and treatment

Cancers

Volumn 6, Issue 1, 2014, Pages 436-458

  Fajardo, Alexandra M ^a   Piazza, Gary A ^a   Tinsley, Heather N ^b  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

^b UNIVERSITY OF MONTEVALLO   (United States)

Author keywords

cAMP; cGMP; Cyclic nucleotide phosphodiesterases; Cyclic nucleotides; PKA; PKG; Protein kinases

Indexed keywords

8 METHOXYMETHYL IBMX; ADENYLATE CYCLASE; AWD 12281; BAY 607550; CILOMILAST; CILOSTAMIDE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; CYCLIC NUCLEOTIDE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; DENBUFYLLINE; DIPYRIDAMOLE; ENZYME INHIBITOR; G PROTEIN COUPLED RECEPTOR; IC 224; IC 933; ICH 224; MILRINONE; PAPAVERINE; RO20 1724; ROFLUMILAST; ROLIPRAM; SH 51866; SILDENAFIL; TADALAFIL; TOLAFENTRINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARDENAFIL; ZAPRINAST;

CANCER PREVENTION; CATALYSIS; CELL ADHESION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME SPECIFICITY; EPITHELIUM TUMOR; HEMATOLOGIC MALIGNANCY; HUMAN; HYDROLYSIS; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR INTERACTION; NEUROTRANSMISSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION;

EID: 84895529193     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers6010436     Document Type: Review

References (133)

1. Gerits, N., Kostenko, S., Shiryaev, A., Johannessen, M., Moens, U. Relations between the mitogen-activated protein kinase and the cAMP-dependent protein kinase pathways: Comradeship and hostility. Cell. Signal. 2008, 20, 1592-1607.
2. Sassone-Corsi, P. The cyclic AMP pathway. Cold Spring Harb. Perspect. Biol. 2012, 4, doi:10.1101/cshperspect.a011148.
3. Rehmann, H., Wittinghofer, A., Bos, J.L. Capturing cyclic nucleotides in action: Snapshots from crystallographic studies. Nat. Rev. Mol. Cell Biol. 2007, 8, 63-73.
4. Taussig, R., Gilman, A.G. Mammalian membrane-bound adenylyl cyclases. J. Biol. Chem. 1995, 270, 1-4.
5. Hanoune, J., Defer, N. Regulation and role of adenylyl cyclase isoforms. Annu. Rev. Pharmacol. Toxicol. 2001, 41, 145-174.
6. Lee, L.C., Maurice, D.H., Baillie, G.S. Targeting protein-protein interactions within the cyclic AMP signaling system as a therapeutic strategy for cardiovascular disease. Future Med. Chem. 2013, 5, 451-464.
7. Buxton, I.L., Brunton, L.L. Compartments of cyclic AMP and protein kinase in mammalian cardiomyocytes. J. Biol. Chem. 1983, 258, 10233-10239.
8. Sodani, K., Patel, A., Kathawala, R.J., Chen, Z.-S. Multidrug resistance associated proteins in multidrug resistance. Chin. J. Cancer 2012, 31, 58-72.
9. Cheepala, S., Hulot, J.S., Morgan, J.A., Sassi, Y., Zhang, W., Naren, A.P., Schuetz, J.D. Cyclic nucleotide compartmentalization: Contributions of phosphodiesterases and ATP-binding cassette transporters. Annu. Rev. Pharmacol. Toxicol. 2013, 53, 231-253.
10. Wielinga, P.R., van der Heijden, I., Reid, G., Beijnen, J.H., Wijnholds, J., Borst, P. Characterization of the MRP4-and MRP5-mediated transport of cyclic nucleotides from intact cells. J. Biol. Chem. 2003, 278, 17664-17671.
11. Omori, K., Kotera, J. Overview of PDEs and their regulation. Circ. Res. 2007, 100, 309-327.
12. Conti, M., Beavo, J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: Essential components in cyclic nucleotide signaling. Annu. Rev. Biochem. 2007, 76, 481-511.
13. Savai, R., Pullamsetti, S.S., Banat, G.A., Weissmann, N., Ghofrani, H.A., Grimminger, F., Schermuly, R.T. Targeting cancer with phosphodiesterase inhibitors. Expert Opin. Investig. Drugs 2010, 19, 117-131.
14. Verhoest, P.R., Chapin, D.S., Corman, M., Fonseca, K., Harms, J.F., Hou, X., Marr, E.S., Menniti, F.S., Nelson, F., O'Connor, R., et al. Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia. J. Med. Chem. 2009, 52, 5188-5196.
15. Dedeurwaerdere, S., Wintmolders, C., Vanhoof, G., Langlois, X. Patterns of brain glucose metabolism induced by phosphodiesterase 10A inhibitors in the mouse: A potential translational biomarker. J. Pharmacol. Exp. Ther. 2011, 339, 210-217.
16. Ceyhan, O., Birsoy, K., Hoffman, C.S. Identification of biologically active PDE11-selective inhibitors using a yeast-based high-throughput screen. Chem. Biol. 2012, 19, 155-163.
17. Bender, A.T., Beavo, J.A. Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use. Pharmacol. Rev. 2006, 58, 488-520.
18. Francis, S.H., Corbin, J.D. Cyclic nucleotide-dependent protein kinases: Intracellular receptors for cAMP and cGMP action. Crit. Rev. Clin. Lab. Sci. 1999, 36, 275-328.
19. Beavo, J.A., Brunton, L.L. Cyclic nucleotide research-Still expanding after half a century. Nat. Rev. Mol. Cell Biol. 2002, 3, 710-718.
20. Beard, M.B., Olsen, A.E., Jones, R.E., Erdogan, S., Houslay, M.D., Bolger, G.B. UCR1 and UCR2 domains unique to the cAMP-specific phosphodiesterase family form a discrete module via electrostatic interactions. J. Biol. Chem. 2000, 275, 10349-10358.
21. Goncalves, R.L., Lugnier, C., Keravis, T., Lopes, M.J., Fantini, F.A., Schmitt, M., Cortes, S.F., Lemos, V.S. The flavonoid dioclein is a selective inhibitor of cyclic nucleotide phosphodiesterase type 1 (PDE1) and a cGMP-dependent protein kinase (PKG) vasorelaxant in human vascular tissue. Eur. J. Pharmacol. 2009, 620, 78-83.
22. Insel, P.A., Zhang, L., Murray, F., Yokouchi, H., Zambon, A.C. Cyclic AMP is both a pro-apoptotic and anti-apoptotic second messenger. Acta Physiol. (Oxf.) 2012, 204, 277-287.
23. Caretta, A., Mucignat-Caretta, C. Protein kinase A in cancer. Cancers 2011, 3, 913-926.
24. Di Benedetto, G., Zoccarato, A., Lissandron, V., Terrin, A., Li, X., Houslay, M.D., Baillie, G.S., Zaccolo, M. Protein kinase A type I and type II define distinct intracellular signaling compartments. Circ. Res. 2008, 103, 836-844.
25. Mayr, B., Montminy, M. Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat. Rev. Mol. Cell Biol. 2001, 2, 599-609.
26. Sakamoto, K.M., Frank, D.A. CREB in the pathophysiology of cancer: Implications for targeting transcription factors for cancer therapy. Clin. Cancer Res. 2009, 15, 2583-2587.
27. Feil, R., Kemp-Harper, B. cGMP signalling: From bench to bedside. Conference on cGMP generators, effectors and therapeutic implications. EMBO Rep. 2006, 7, 149-153.
28. Beavo, J.A. Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms. Physiol. Rev. 1995, 75, 725-748.
29. Lincoln, T.M., Cornwell, T.L. Intracellular cyclic GMP receptor proteins. FASEB J. 1993, 7, 328-338.
30. Browning, D.D. Protein kinase G as a therapeutic target for the treatment of metastatic colorectal cancer. Expert Opin. Ther. Targets 2008, 12, 367-376.
31. Das, A., Xi, L., Kukreja, R.C. Protein kinase G-dependent cardioprotective mechanism of phosphodiesterase-5 inhibition involves phosphorylation of ERK and GSK3beta. J. Biol. Chem. 2008, 283, 29572-29585.
32. Ruth, P. Cyclic GMP-dependent protein kinases: Understanding in vivo functions by gene targeting. Pharmacol. Ther. 1999, 82, 355-372.
33. Francis, S.H., Busch, J.L., Corbin, J.D., Sibley, D. cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol. Rev. 2010, 62, 525-563.
34. Kwon, I.K., Wang, R., Thangaraju, M., Shuang, H., Liu, K., Dashwood, R., Dulin, N., Ganapathy, V., Browning, D.D. PKG inhibits TCF signaling in colon cancer cells by blocking beta-catenin expression and activating FOXO4. Oncogene 2010, 29, 3423-3434.
35. Thompson, W.J., Piazza, G.A., Li, H., Liu, L., Fetter, J., Zhu, B., Sperl, G., Ahnen, D., Pamukcu, R. Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res. 2000, 60, 3338-3342.
36. Deguchi, A., Thompson, W.J., Weinstein, I.B. Activation of protein kinase G is sufficient to induce apoptosis and inhibit cell migration in colon cancer cells. Cancer Res. 2004, 64, 3966-3973.
37. Liu, L., Li, H., Underwood, T., Lloyd, M., David, M., Sperl, G., Pamukcu, R., Thompson, W.J. Cyclic GMP-dependent protein kinase activation and induction by exisulind and CP461 in colon tumor cells. J. Pharmacol. Exp. Ther. 2001, 299, 583-592.
38. Deguchi, A., Soh, J.W., Li, H., Pamukcu, R., Thompson, W.J., Weinstein, I.B. Vasodilator-stimulated phosphoprotein (VASP) phosphorylation provides a biomarker for the action of exisulind and related agents that activate protein kinase G. Mol. Cancer Ther. 2002, 1, 803-809.
39. Drees, M., Zimmermann, R., Eisenbrand, G. 3',5'-Cyclic nucleotide phosphodiesterase in tumor cells as potential target for tumor growth inhibition. Cancer Res. 1993, 53, 3058-3061.
40. Piazza, G.A., Thompson, W.J., Pamukcu, R., Alila, H.W., Whitehead, C.M., Liu, L., Fetter, J.R., Gresh, W.E., Jr., Klein-Szanto, A.J., Farnell, D.R., et al. Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis. Cancer Res. 2001, 61, 3961-3968.
41. Whitehead, C.M., Earle, K.A., Fetter, J., Xu, S., Hartman, T., Chan, D.C., Zhao, T.L., Piazza, G., Klein-Szanto, A.J., Pamukcu, R., et al. Exisulind-induced apoptosis in a non-small cell lung cancer orthotopic lung tumor model augments docetaxel treatment and contributes to increased survival. Mol. Cancer Ther. 2003, 2, 479-488.
42. Zhu, B., Strada, S.J. The novel functions of cGMP-specific phosphodiesterase 5 and its inhibitors in carcinoma cells and pulmonary/cardiovascular vessels. Curr. Top. Med. Chem. 2007, 7, 437-454.
43. Zhu, B., Strada, S., Stevens, T. Cyclic GMP-specific phosphodiesterase 5 regulates growth and apoptosis in pulmonary endothelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 2005, 289, L196-L206.
44. Jiang, X., Li, J., Paskind, M., Epstein, P.M. Inhibition of calmodulin-dependent phosphodiesterase induces apoptosis in human leukemic cells. Proc. Natl. Acad. Sci. USA 1996, 93, 11236-11241.
45. Kloster, M.M., Hafte, T.T., Moltzau, L.R., Naderi, E.H., Dahle, M.K., Skålhegg, B.S., Gaudernack, G., Levy, F.O., Naderi, S., Blomhoff, H.K. EBV infection renders B cells resistant to growth inhibition via adenylyl cyclase. Cell. Signal. 2008, 20, 1169-1178.
46. Lerner, A., Epstein, P.M. Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies. Biochem. J. 2006, 393, 21-41.
47. Chawla, R.K., Shlaer, S.M., Lawson, D.H., Murray, T.G., Schmidt, F., Shoji, M., Nixon, D.W., Richmond, A., Rudman, D. Elevated plasma and urinary guanosine 3':5'-monophosphate and increased production rate in patients with neoplastic diseases. Cancer Res. 1980, 40, 3915-3920.
48. Chawla, R.K., Nixon, D.W., Shoji, M., Rudman, D. Plasma and urine cyclic guanosine 3':5'-monophosphate in disseminated cancer. Ann. Intern. Med. 1979, 91, 862-864.
49. Aleksijevic, A., Lang, J.M., Giron, C., Stoclet, J.C., Mayer, S., Oberling, F. Alterations of peripheral blood lymphocyte cyclic AMP and cyclic GMP in untreated patients with hodgkin's disease. Clin. Immunol. Immunopathol. 1983, 26, 398-405.
50. Aleksijevic, A., Lugnier, C., Giron, C., Mayer, S., Stoclet, J.C., Lang, J.M. Cyclic AMP and cyclic GMP phosphodiesterase activities in Hodgkin's disease lymphocytes. Int. J. Immunopharmacol. 1987, 9, 525-531.
51. Carlson, C.C., Smithers, S.L., Yeh, K.A., Burnham, L.L., Dransfield, D.T. Protein kinase A regulatory subunits in colon cancer. Neoplasia 1999, 1, 373-378.
52. Ciardiello, F., Pepe, S., Bianco, C., Baldassarre, G., Ruggiero, A., Bianco, C., Selvam, M.P., Bianco, A.R., Tortora, G. Down-regulation of RI alpha subunit of cAMP-dependent protein kinase induces growth inhibition of human mammary epithelial cells transformed by c-Ha-ras and c-erbB-2 proto-oncogenes. Int. J. Cancer 1993, 53, 438-443.
53. DeRubertis, F.R., Craven, P.A. Sequential alterations in the hepatic content and metabolism of cyclic AMP and cyclic GMP induced by DL-ethionine: Evidence for malignant transformation of liver with a sustained increase in cyclic AMP. Metabolism 1976, 25, 1611-1625.
54. Heinonen, P.K., Metsa-Ketela, T. Prostanoids and cyclic nucleotides in malignant and benign ovarian tumors. Med. Oncol. Tumor Pharmacother. 1988, 5, 11-15.
55. Pertuit, M., Barlier, A., Enjalbert, A., Gérard, C. Signalling pathway alterations in pituitary adenomas: Involvement of Gsalpha, cAMP and mitogen-activated protein kinases. J. Neuroendocrinol. 2009, 21, 869-877.
56. Ahn, Y.H., Jung, J.M., Hong, S.H. 8-Chloro-cyclic AMP-induced growth inhibition and apoptosis is mediated by p38 mitogen-activated protein kinase activation in HL60 cells. Cancer Res. 2005, 65, 4896-4901.
57. Michalides, R., Griekspoor, A., Balkenende, A., Verwoerd, D., Janssen, L., Jalink, K., Floore, A., Velds, A., van't Veer, L., Neefjes, J. Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer. Cancer Cell 2004, 5, 597-605.
58. Schuller, H.M. Effects of tobacco constituents and psychological stress on the beta-adrenergic regulation of non-small cell lung cancer and pancreatic cancer: Implications for intervention. Cancer Biomark. 2013, 13, 133-144.
59. Wharton, J., Strange, J.W., Møller, G.M., Growcott, E.J., Ren, X., Franklyn, A.P., Phillips, S.C., Wilkins, M.R. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am. J. Respir. Crit. Care Med. 2005, 172, 105-113.
60. Zhu, B., Vemavarapu, L., Thompson, W.J., Strada, S.J. Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells. J. Cell. Biochem. 2005, 94, 336-350.
61. Kool, M., de Haas, M., Scheffer, G.L., Scheper, R.J., van Eijk, M.J., Juijn, J.A., Baas, F., Borst, P. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 1997, 57, 3537-3547.
62. Singer, A.L., Sherwin, R.P., Dunn, A.S., Appleman, M.M. Cyclic nucleotide phosphodiesterases in neoplastic and nonneoplastic human mammary tissues. Cancer Res. 1976, 36, 60-66.
63. Cohen, L.A., Straka, D., Chan, P.C. Cyclic nucleotide phosphodiesterase activity in normal and neoplastic rat mammary cells grown in monolayer culture. Cancer Res. 1976, 36, 2007-2012.
64. Tinsley, H.N., Gary, B.D., Keeton, A.B., Zhang, W., Abadi, A.H., Reynolds, R.C., Piazza, G.A. Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G. Mol. Cancer Ther. 2009, 8, 3331-3340.
65. Li, P., Schulz, S., Bombonati, A., Palazzo, J.P., Hyslop, T.M., Xu, Y., Baran, A.A., Siracusa, L.D., Pitari, G.M., Waldman, S.A. Guanylyl cyclase C suppresses intestinal tumorigenesis by restricting proliferation and maintaining genomic integrity. Gastroenterology 2007, 133, 599-607.
66. Zhang, L., Murray, F., Zahno, A., Kanter, J.R., Chou, D., Suda, R., Fenlon, M., Rassenti, L., Cottam, H., Kipps, T.J., et al. Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 2008, 105, 19532-19537.
67. Marko, D., Pahlke, G., Merz, K.H., Eisenbrand, G. Cyclic 3',5'-nucleotide phosphodiesterases: Potential targets for anticancer therapy. Chem. Res. Toxicol. 2000, 13, 944-948.
68. Kobsar, A., Heeg, S., Krohne, K., Opitz, A., Walter, U., Böck, M., Gambaryan, S., Eigenthaler, M. Cyclic nucleotide-regulated proliferation and differentiation vary in human hematopoietic progenitor cells derived from healthy persons, tumor patients, and chronic myelocytic leukemia patients. Stem Cells Dev. 2008, 17, 81-91.
69. Kiefer, J., Okret, S., Jondal, M., McConkey, D.J. Functional glucocorticoid receptor expression is required for cAMP-mediated apoptosis in a human leukemic T cell line. J. Immunol. 1995, 155, 4525-4528.
70. Tortorella, C., Piazzolla, G., Spaccavento, F., Antonaci, S. Effects of granulocyte-macrophage colony-stimulating factor and cyclic AMP interaction on human neutrophil apoptosis. Mediat. Inflamm. 1998, 7, 391-396.
71. Martin, M.C., Dransfield, I., Haslett, C., Rossi, A.G. Cyclic AMP regulation of neutrophil apoptosis occurs via a novel protein kinase A-independent signaling pathway. J. Biol. Chem. 2001, 276, 45041-45050.
72. Garcia-Bermejo, L., Pérez, C., Vilaboa, N.E., de Blas, E., Aller, P. cAMP increasing agents attenuate the generation of apoptosis by etoposide in promonocytic leukemia cells. J. Cell Sci. 1998, 111, 637-644.
73. Monahan, T.M., Marchand, N.W., Fritz, R.R., Abell, C.W. Cyclic adenosine 3':5'-monophosphate levels and activities of related enzymes in normal and leukemic lymphocytes. Cancer Res. 1975, 35, 2540-2547.
74. Carpentieri, U., Monahan, T.M., Gustavson, L.P. Observations on the level of cyclic nucleotides in three population of human lymphocytes in culture. J. Cycl. Nucleotide Res. 1980, 6, 253-259.
75. Lee, R., Wolda, S., Moon, E., Esselstyn, J., Hertel, C., Lerner, A. PDE7A is expressed in human B-lymphocytes and is up-regulated by elevation of intracellular cAMP. Cell. Signal. 2002, 14, 277-284.
76. Flamigni, F., Facchini, A., Stanic, I., Tantini, B., Bonavita, F., Stefanelli, C. Control of survival of proliferating L1210 cells by soluble guanylate cyclase and p44/42 mitogen-activated protein kinase modulators. Biochem. Pharmacol. 2001, 62, 319-328.
77. Cho, E.C., Mitton, B., Sakamoto, K.M. CREB and leukemogenesis. Crit. Rev. Oncog. 2011, 16, 37-46.
78. Camici, M. Guanylin peptides and colorectal cancer (CRC). Biomed. Pharmacother. 2008, 62, 70-76.
79. Birbe, R., Palazzo, J.P., Walters, R., Weinberg, D., Schulz, S., Waldman, S.A. Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract. Hum. Pathol. 2005, 36, 170-179.
80. Steinbrecher, K.A., Wowk, S.A., Rudolph, J.A., Witte, D.P., Cohen, M.B. Targeted inactivation of the mouse guanylin gene results in altered dynamics of colonic epithelial proliferation. Am. J. Pathol. 2002, 161, 2169-2178.
81. Waldman, S.A., Barber, M., Pearlman, J., Park, J., George, R., Parkinson, S.J. Heterogeneity of guanylyl cyclase C expressed by human colorectal cancer cell lines in vitro. Cancer Epidemiol. Biomark. Prev. 1998, 7, 505-514.
82. Pitari, G.M., Zingman, L.V., Waldman, S.A. Bacterial enterotoxins are associated with resistance to colon cancer. Proc. Natl. Acad. Sci. USA 2003, 100, 2695-2699.
83. Johansson, C.C., Yndestad, A., Enserink, J.M., Ree, A.H., Aukrust, P., Taskén, K. The epidermal growth factor-like growth factor amphiregulin is strongly induced by the adenosine 3',5'-monophosphate pathway in various cell types. Endocrinology 2004, 145, 5177-5184.
84. Kung, W., Bechtel, E., Geyer, E., Salokangas, A., Preisz, J., Huber, P., Torhorst, J., Jungmann, R.A., Talmadge, K., Eppenberger, U. Altered levels of cyclic nucleotides, cyclic AMP phosphodiesterase and adenylyl cyclase activities in normal, dysplastic and neoplastic human mammary tissue. FEBS Lett. 1977, 82, 102-106.
85. Whitfield, J.F., Boynton, A.L., MacManus, J.P., Rixon, R.H., Sikorska, M., Tsang, B., Walker, P.R., Swierenga, S.H. The roles of calcium and cyclic AMP in cell proliferation. Ann. NY Acad. Sci. 1980, 339, 216-240.
86. Jedlitschky, G., Burchell, B., Keppler, D. The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J. Biol. Chem. 2000, 275, 30069-30074.
87. Borland, G., Smith, B.O., Yarwood, S.J. EPAC proteins transduce diverse cellular actions of cAMP. Br. J. Pharmacol. 2009, 158, 70-86.
88. Li, P., Lin, J.E., Chervoneva, I., Schulz, S., Waldman, S.A., Pitari, G.M. Homeostatic control of the crypt-villus axis by the bacterial enterotoxin receptor guanylyl cyclase C restricts the proliferating compartment in intestine. Am. J. Pathol. 2007, 171, 1847-1858.
89. Pitari, G.M., di Guglielmo, M.D., Park, J., Schulz, S., Waldman, S.A. Guanylyl cyclase C agonists regulate progression through the cell cycle of human colon carcinoma cells. Proc. Natl. Acad. Sci. USA 2001, 98, 7846-7851.
90. Mann, E.A., Steinbrecher, K.A., Stroup, C., Witte, D.P., Cohen, M.B., Giannella, R.A. Lack of guanylyl cyclase C, the receptor for Escherichia coli heat-stable enterotoxin, results in reduced polyp formation and increased apoptosis in the multiple intestinal neoplasia (Min) mouse model. Int. J. Cancer 2005, 116, 500-505.
91. Lugnier, C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents. Pharmacol. Ther. 2006, 109, 366-398.
92. 2+ responses are differentially modulated by nitric oxide via activation of a cyclic GMP-dependent pathway. Mol. Pharmacol. 1995, 48, 1068-1077.
93. Lucas, K.A., Pitari, G.M., Kazerounian, S., Ruiz-Stewart, I., Park, J., Schulz, S., Chepenik, K.P., Waldman, S.A. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol. Rev. 2000, 52, 375-414.
94. Chen, H., Levine, Y.C., Golan, D.E., Michel, T., Lin, A.J. Atrial natriuretic peptide-initiated cGMP pathways regulate vasodilator-stimulated phosphoprotein phosphorylation and angiogenesis in vascular endothelium. J. Biol. Chem. 2008, 283, 4439-4447.
95. Idriss, S.D., Gudi, T., Casteel, D.E., Kharitonov, V.G., Pilz, R.B., Boss, G.R. Nitric oxide regulation of gene transcription via soluble guanylate cyclase and type I cGMP-dependent protein kinase. J. Biol. Chem. 1999, 274, 9489-9493.
96. Pilz, R.B., Casteel, D.E. Regulation of gene expression by cyclic GMP. Circ. Res. 2003, 93, 1034-1046.
97. Wong, J.C., Bathina, M., Fiscus, R.R. Cyclic GMP/protein kinase G type-Ialpha (PKG-Ialpha) signaling pathway promotes CREB phosphorylation and maintains higher c-IAP1, livin, survivin, and Mcl-1 expression and the inhibition of PKG-Ialpha kinase activity synergizes with cisplatin in non-small cell lung cancer cells. J. Cell. Biochem. 2012, 113, 3587-3598.
98. Zhou, L., Hosohata, K., Gao, S., Gu, Z., Wang, Z. cGMP-dependent protein kinase Ibeta interacts with p44/WDR77 to regulate androgen receptor-driven gene expression. PLoS One 2013, 8, e63119.
99. Lan, T., Chen, Y., Sang, J., Wu, Y., Wang, Y., Jiang, L., Tao, Y. Type II cGMP-dependent protein kinase inhibits EGF-induced MAPK/JNK signal transduction in breast cancer cells. Oncol. Rep. 2012, 27, 2039-2044.
100. Lubbe, W.J., Zhou, Z.Y., Fu, W., Zuzga, D., Schulz, S., Fridman, R., Muschel, R.J., Waldman, S.A., Pitari, G.M. Tumor epithelial cell matrix metalloproteinase 9 is a target for antimetastatic therapy in colorectal cancer. Clin. Cancer Res. 2006, 12, 1876-1882.
101. Seamon, K.B., Padgett, W., Daly, J.W. Forskolin: Unique diterpene activator of adenylate cyclase in membranes and in intact cells. Proc. Natl. Acad. Sci. USA 1981, 78, 3363-3367.
102. Agarwal, K.C., Parks, R.E., Jr. Forskolin: A potential antimetastatic agent. Int. J. Cancer 1983, 32, 801-804.
103. Chen, T.C., Hinton, D.R., Zidovetzki, R., Hofman, F.M. Up-regulation of the cAMP/PKA pathway inhibits proliferation, induces differentiation, and leads to apoptosis in malignant gliomas. Lab. Investig. 1998, 78, 165-174.
104. Li, Z., Wang, J. A forskolin derivative, FSK88, induces apoptosis in human gastric cancer BGC823 cells through caspase activation involving regulation of Bcl-2 family gene expression, dissipation of mitochondrial membrane potential and cytochrome c release. Cell Biol. Int. 2006, 30, 940-946.
105. Shayo, C., Legnazzi, B.L., Monczor, F., Fernández, N., Riveiro, M.E., Baldi, A., Davio, C. The time-course of cyclic AMP signaling is critical for leukemia U-937 cell differentiation. Biochem. Biophys. Res. Commun. 2004, 314, 798-804.
106. Baumann, G., Felix, S., Sattelberger, U., Klein, G. Cardiovascular effects of forskolin (HL 362) in patients with idiopathic congestive cardiomyopathy-A comparative study with dobutamine and sodium nitroprusside. J. Cardiovasc. Pharmacol. 1990, 16, 93-100.
107. Christenson, J.T., Thulesius, O., Nazzal, M.M. The effect of forskolin on blood flow, platelet metabolism, aggregation and ATP release. Vasa 1995, 24, 56-61.
108. Ding, X., Staudinger, J.L. Induction of drug metabolism by forskolin: The role of the pregnane X receptor and the protein kinase a signal transduction pathway. J. Pharmacol. Exp. Ther. 2005, 312, 849-856.
109. Barron, T.I., Sharp, L., Visvanathan, K. Beta-adrenergic blocking drugs in breast cancer: A perspective review. Ther. Adv. Med. Oncol. 2012, 4, 113-125.
110. Ganz, P.A., Cole, S.W. Expanding our therapeutic options: Beta blockers for breast cancer? J. Clin. Oncol. 2011, 29, 2612-2616.
111. Fitzgerald, P.J. Beta blockers, norepinephrine, and cancer: An epidemiological viewpoint. Clin. Epidemiol. 2012, 4, 151-156.
112. Wang, H.M., Liao, Z.X., Komaki, R., Welsh, J.W., O'Reilly, M.S., Chang, J.Y., Zhuang, Y., Levy, L.B., Lu, C., Gomez, D.R. Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy. Ann. Oncol. 2013, 24, 1312-1319.
113. Garg, U.C., Hassid, A. Inhibition of rat mesangial cell mitogenesis by nitric oxide-generating vasodilators. Am. J. Physiol. 1989, 257, F60-F66.
114. Garg, U.C., Hassid, A. Nitric oxide-generating vasodilators inhibit mitogenesis and proliferation of BALB/C 3T3 fibroblasts by a cyclic GMP-independent mechanism. Biochem. Biophys. Res. Commun. 1990, 171, 474-479.
115. Gu, M., Lynch, J., Brecher, P. Nitric oxide increases p21(Waf1/Cip1) expression by a cGMP-dependent pathway that includes activation of extracellular signal-regulated kinase and p70(S6k). J. Biol. Chem. 2000, 275, 11389-11396.
116. Hagos, G.K., Abdul-Hay, S.O., Sohn, J., Edirisinghe, P.D., Chandrasena, R.E., Wang, Z., Li, Q., Thatcher, G.R. Anti-inflammatory, antiproliferative, and cytoprotective activity of NO chimera nitrates of use in cancer chemoprevention. Mol. Pharmacol. 2008, 74, 1381-1391.
117. Rigas, B., Williams, J.L. NO-donating NSAIDs and cancer: An overview with a note on whether NO is required for their action. Nitric Oxide 2008, 19, 199-204.
118. Sostres, C., Gargallo, C.J., Arroyo, M.T., Lanas, A. Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract. Res. Clin. Gastroenterol. 2010, 24, 121-132.
119. Shami, P.J., Saavedra, J.E., Bonifant, C.L., Chu, J., Udupi, V., Malaviya, S., Carr, B.I., Kar, S., Wang, M., Jia, L., et al. Antitumor activity of JS-K [O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate] and related O2-aryl diazeniumdiolates in vitro and in vivo. J. Med. Chem. 2006, 49, 4356-4366.
120. Bischoff, E. Potency, selectivity, and consequences of nonselectivity of PDE inhibition. Int. J. Impot. Res. 2004, 16, S11-S14.
121. Tinsley, H.N., Gary, B.D., Keeton, A.B., Lu, W.Y., Li, Y.H., Piazza, G.A. Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic Wnt/beta-cateninmediated transcription in human breast tumor cells. Cancer Prev. Res. (Phila.) 2011, 4, 1275-1284.
122. Tinsley, H.N., Gary, B.D., Thaiparambil, J., Li, N., Lu, W., Li, Y., Maxuitenko, Y.Y., Keeton, A.B., Piazza, G.A. Colon tumor cell growth-inhibitory activity of sulindac sulfide and other nonsteroidal anti-inflammatory drugs is associated with phosphodiesterase 5 inhibition. Cancer Prev. Res. (Phila.) 2010, 3, 1303-1313.
123. Hirsh, L., Dantes, A., Suh, B.S., Yoshida, Y., Hosokawa, K., Tajima, K., Kotsuji, F., Merimsky, O., Amsterdam, A. Phosphodiesterase inhibitors as anti-cancer drugs. Biochem. Pharmacol. 2004, 68, 981-988.
124. Erikstein, B.S., McCormack, E., Tronstad, K.J., Schwede, F., Berge, R., Gjertsen, B.T. Protein kinase A activators and the pan-PPAR agonist tetradecylthioacetic acid elicit synergistic anti-leukaemic effects in AML through CREB. Leuk. Res. 2010, 34, 77-84.
125. Mantovani, G., Bondioni, S., Lania, A.G., Rodolfo, M., Peverelli, E., Polentarutti, N., Veliz Rodriguez, T., Ferrero, S., Bosari, S., Beck-Peccoz, P., et al. High expression of PKA regulatory subunit 1A protein is related to proliferation of human melanoma cells. Oncogene 2008, 27, 1834-1843.
126. Bouizar, Z., Ragazzon, B., Viou, L., Hortane, M., Bertherat, J., Rizk-Rabin, M. 8Cl-cAMP modifies the balance between PKAR1 and PKAR2 and modulates the cell cycle, growth and apoptosis in human adrenocortical H295R cells. J. Mol. Endocrinol. 2010, 44, 331-347.
127. Cen, B., Deguchi, A., Weinstein, I.B. Activation of protein kinase G Increases the expression of p21CIP1, p27KIP1, and histidine triad protein 1 through Sp1. Cancer Res. 2008, 68, 5355-5362.
128. Kwon, I.K., Schoenlein, P.V., Delk, J., Liu, K., Thangaraju, M., Dulin, N.O., Ganapathy, V., Berger, F.G., Browning, D.D. Expression of cyclic guanosine monophosphate-dependent protein kinase in metastatic colon carcinoma cells blocks tumor angiogenesis. Cancer 2008, 112, 1462-1470.
129. Hou, Y., Wong, E., Martin, J., Schoenlein, P.V., Dostmann, W.R., Browning, D.D. A role for cyclic-GMP dependent protein kinase in anoikis. Cell. Signal. 2006, 18, 882-888.
130. Soh, J.W., Kazi, J.U., Li, H., Thompson, W.J., Weinstein, I.B. Celecoxib-induced growth inhibition in SW480 colon cancer cells is associated with activation of protein kinase G. Mol. Carcinog. 2008, 47, 519-525.
131. Fallahian, F., Karami-Tehrani, F., Salami, S., Aghaei, M. Cyclic GMP induced apoptosis via protein kinase G in oestrogen receptor-positive and -negative breast cancer cell lines. FEBS J. 2011, 278, 3360-3369.
132. Ausserlechner, M.J., Hagenbuchner, J., Fuchs, S., Geiger, K., Obexer, P. FOXO Transcription Factors as Potential Therapeutic Targets in Neuroblastoma, in Neuroblastoma-Present and Future; InTech: Rijeka, Croatia, 2012.
133. Edwards, B.K., Ward, E., Kohler, B.A., Eheman, C., Zauber, A.G., Anderson, R.N., Jemal, A., Schymura, M.J., Lansdorp-Vogelaar, I., Seeff, L.C., et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010, 116, 544-573.